Dear Investors,

​For oncology investors, some of the most compelling opportunities emerge when a company moves from clinical hypothesis to clinical proof.

​Angiex is advancing a novel approach to solid tumors with AGX101, an investigational Phase 1 antibody-drug conjugate (ADC) targeting TM4SF1 in tumor-associated vasculature and TM4SF1-expressing tumor cells.

​Company Overview

​AGX101 is designed to deliver its cytotoxic payload to both tumor blood vessels and tumor cells, creating a differentiated dual-targeting approach with potential across multiple solid tumor indications. Clinical data from 36 patients show exploratory evidence of on-tumor activity, with additional PET and ctDNA data expected to further characterize treatment response.

​

Why Investors Are Taking Notice

• ​Clinical-stage asset: AGX101 is already in Phase 1 development.

• ​Broad potential: TM4SF1 expression supports evaluation across multiple solid tumors.

• ​Upcoming catalysts: Recommended Phase 2 dose selection, additional efficacy data, and FDA engagement represent key near-term milestones.

• ​Financing opportunity: Angiex is raising a $10M top-off financing to advance AGX101 toward proof of concept.